EPF Acknowledgement of financial support 2016
| Industry related income | ||
| Name of company/ funder | Amount of income | % of overall organisation’s income |
| ALMIRALL | € 5.000,00 | 0,26% |
| AbbVie | € 25.000,00 | 1,32% |
| GILEAD | € 20.000,00 | 1,05% |
| GSK | € 60.000,00 | 3,16% |
| MSD | € 58.891,61 | 3,10% |
| PFIZER | € 67.700,00 | 3,55% |
| NOVARTIS | € 60.000,00 | 3,16% |
| SANOFI PASTEUR MSD | € 10.000,00 | 0,53% |
| Alexion | € 10.000,00 | 0,53% |
| AIFP | € 20.000,00 | 1,05% |
| Baxter World Trade | € 10.000,00 | 0,53% |
| Celgene | € 15.000,00 | 0,79% |
| Janssen | € 30.000,00 | 1,58% |
| Eli Lilly | € 15.000,00 | 0,79% |
| Hoffmann-La Roche | € 40.000,00 | 2,110% |
| Vertex | € 15.000,00 | 0,79% |
| Bosch Foundation | € 20.000,00 | 1,05% |
| CSL Behring | € 10.000,00 | 0,53% |
| Grünenthal | € 10.000,00 | 0,53% |
| Mylan | € 10.000,00 | 0,53% |
| Sanofi-Aventis | € 40.000,00 | 2,11% |
| Laboratoires Servier | € 10.000,00 | 0,53% |
| Shire | € 10.000,00 | 0,53% |
| TEVA | € 20.000,00 | 1,05% |
| J&J | € 10.000,00 | 0,53% |
| Pharma industry EUPATI consortium cash pot (UCB, Amgen, Genzyme, VFA, AZ, Novonordisk, Bayer, Merck, Janssen, GSK, Chiesi, Hoffmann, Lilly, Novartis, Esteve) | € 62.709,74 | 3,30% |
| Subtotal: | € 664.301,35 | 34.97% |
| Non-industry related income | ||
| Source of funding | Amount of income | % of overall organisation’s income |
| European Commission | € 731.835,98 | 38,52% |
| SmartCare | € 4.600,59 | 0,24% |
| Eupati | € 309.753,53 | 16,30% |
| Adapt Smart | € 24.886,69 | 1,31% |
| Joint Action PASQ | € 2.598,32 | 0,14% |
| Joint Action CHRODIS | € 22.059,72 | 1,16% |
| Prefer | € 1.594,45 | 0,08% |
| PISCE Self Care Tender | € 4.421,70 | 0,23% |
| ProStep | € 89.345,89 | 4,70% |
| Membership and subscriptions and other income | € 44.360,23 | 2,34% |
| Subtotal: | € 1.235.457,10 | 65,02% |
| TOTAL: | € 1.899.758,45 | 100,00% |